Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Recently Viewed
OCGN
Ocugen
MRK
Merck Company
QUIK
QuickLogic
NOA
North American Constructi
MA
Mastercard
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
OCGN
Ocugen
$1.77
Login to see Ocugen (OCGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Chart
$1.03 (+71.84%)
$1.12 (+58.04%)
$0.7 (+152.86%)
$0.94 (+88.30%)
OCGN has Medium Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Price under $5
OCGN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
OCGN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
OCGN Street view is extremely bullish but have mixed views on the near-term outlook
Average key support and resistance price levels.
Login to displayOCGN Earnings
The TTM reflects 12-month period, providing review of OCGN financial performance.
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
What is OCGN current stock price?
What are OCGN stock strengths?
What risks are associated with OCGN stock?
When is OCGN next earnings report?
What is OCGN market cap and volume?
What is OCGN's current Stock IQ?
Should I buy OCGN stock right now?
Is OCGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for OCGN?
What does a 'Strong Sell' rating mean for OCGN?
What factors influence OCGN's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Recently Viewed
OCGN
Ocugen
MRK
Merck Company
QUIK
QuickLogic
NOA
North American Constructi
MA
Mastercard
Most Trending
+34.28%
+6.50%
-6.76%
+1.93%
+1.43%
OCGN
Ocugen
Current Price
$1.77
Stock Insights
Not Enough Information
Login to unlock Ocugen (OCGN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$1.03 (+71.84%)
$1.12 (+58.04%)
$0.7 (+152.86%)
$0.94 (+88.30%)
OCGN Analysts Opinion
OCGN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
OCGN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
OCGN Street view is extremely bullish but have mixed views on the near-term outlook
OCGN has Medium Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Price under $5
Average key support and resistance price levels.
Login to displayOCGN Earnings
The TTM data reflects the most recent 12-month period, providing overview of OCGN financial performance.
OCGN Financial Health
The company financial health is gradually deteriorating, indicating rising risks and weakening fundamentals
Financial Score
OCGN Latest Analysis
Ocugen to Present at Industry and Investor Conferences in October 2025. th Annual Genetic Medicines Conference and the 2025 Maxim Growth Summit.
Thu Oct 2, 2025
Forecasting The Future: 4 Analyst Projections For Ocugen. 4 analysts have expressed a variety of opinions on Ocugen (NASDAQ:) over the past quarter offering a diverse set of opinions from ish to bearish.The following table summarizes their recent ratings shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.4000010000000001000020000In the assessment of 12-month price targets analysts unveil insights for Ocugen presenting an average target of
Fri Sep 19, 2025
Ocugen gets EU approval for Prolia and Xgeva biosimilars.
Fri Sep 19, 2025
Why Ocugen Stock Zoomed 12% Higher Today. Key PointsThe company signed a licensing agreement with South Koreas Kawngdong Pharmaceutical.
Mon Sep 15, 2025
Ocugen Shares Are Trading Higher Monday: Whats Going On?. ) shares traded higher on Monday after the company announced a licensing agreement with .OCGN shares are powering higher on strong volume. Under the agreement Ocugen will receive upfront license fees and near-term development milestone payments totaling up to $7.5 million. The company will ...
Mon Sep 15, 2025
Ocugen Inc. and Kwangdong Pharmaceutical Co. Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea. MALVERN Pa. Sept. 15 2025 (GLOBE NEWSWIRE) -- Ocugen Inc. (Ocugen or the Company) (NASDAQ: OCGN) a pioneering biotechnology leader in gene therapies for blindness diseases today executed a licensing agreement with Kwangdong Pharmaceutical Co. Ltd. (Kwangdong) one of the leading pharmaceutical companies in Korea for the exclusive Korean rights to OCU400—O
Mon Sep 15, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
OCGN Stock trends
OCGN Stock performance
OCGN Stock analysis
OCGN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings